In another in vivo model, a significant delay in tumor growth and an improved survival rate were obtained using the anti-EGFR-TiO2-UCNs conjugate compared to conventional chlorin-e6 (Ce6) treatment [230]. This evidence concerns the gene EGFR and neoplasm.